- Conditions
- Surgery, Coronary Artery Disease
- Interventions
- Rocuronium, Neostigmine, Glycopyrrolate, Sugammadex
- Drug
- Lead sponsor
- West Virginia University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–17
of 17
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Kidney Transplant; Complications, Postoperative Residual Curarization, Postoperative Residual Weakness
- Interventions
- Sugammadex, Neostigmine
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Post-operative Nausea and Vomiting, Laparoscopic Sleeve Gastrectomy
- Interventions
- Aprepitant 80 mg Oral Capsule, scopolamine transdermal, Total intravenous anesthesia, Dexamethasone, Ondansetron, Reglan, Compazine, Sugammadex, Propofol, dexmedetomidine, Fentanyl, Sevoflurane, Desflurane
- Drug · Procedure
- Lead sponsor
- Stony Brook University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Stony Brook, New York
- Conditions
- Reversal of Neuromuscular Blockade
- Interventions
- Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Sugammadex 16 mg/kg, Neostigmine + Glycopyrrolate, Rocuronium, Vecuronium
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 344 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Loma Linda, California + 15 more
- Conditions
- Residual Paralysis, Post Anesthesia
- Interventions
- Protocol for Management of Muscle Relaxation With Rocuronium Using Objective Monitoring and Reversal With Neostigmine or Sugammadex
- Combination Product
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Coronary Artery Bypass Graft and/or Aortic Valve Replacement Surgery
- Interventions
- Sugammadex, Placebo
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Neuromuscular Blockade
- Interventions
- Group A. "Muscle relaxant #1": rocuronium + sugammadex; "Muscle relaxant #2": succinylcholine +saline, Group B. "Muscle relaxant #2": succinylcholine +saline; "Muscle relaxant #1": rocuronium + sugammadex;
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Surgery
- Interventions
- Sugammadex, Placebo
- Drug · Other
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 21 Years to 90 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Evanston, Illinois
- Conditions
- Coronary Artery Disease, Valvular Heart Disease, Aorta Disease, Heart Failure
- Interventions
- Sugammadex administration
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Respiratory Complication, Obstructive Sleep Apnea
- Interventions
- Sugammadex 100 MG/ML [Bridion]
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12,248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Bradycardia
- Interventions
- Recording heart rate changes
- Other
- Lead sponsor
- Joseph D. Tobias
- Other
- Eligibility
- Up to 18 Years
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Neuromuscular Blockade
- Interventions
- Neostigmine with glycopyrrolate, Sugammadex
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Residual Neuromuscular Blockade
- Interventions
- TetraGraph
- Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Renal Insufficiency, Renal Impairment
- Interventions
- sugammadex
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Hialeah, Florida
- Conditions
- Laparoscopic Gastric Bypass Surgery, Ketamine
- Interventions
- Ketamine, Standard therapy
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 69 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Neuromuscular Blockade
- Interventions
- Sugammadex 2 mg/kg ABW, Sugammadex 2 mg/kg IBW, Sugammadex 4 mg/kg ABW, Sugammadex 4 mg/kg IBW, Neostigmine + Glycopyrrolate, Rocuronium or Vecuronium
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 13
- States / cities
- Sacramento, California • Miami, Florida • Kansas City, Kansas + 9 more
- Conditions
- Neuromuscular Blocking Agents, Urinary Retention After Procedure, Urinary Retention Postoperative, Neuromuscular Blockade Reversal Agent, Neuromuscular Blockade, Costs, Atropine, Sugammadex, Glycopyrrolate, Neostigmine, Anesthesia
- Interventions
- Choice of reversal agent (sugammadex or neostigmine [with muscaranic antagonist])
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts